Fibroblast growth factor 9 (FGF9) promotes cancer progression; however, its role in cell proliferation related to tumorigenesis remains elusive. We investigated how FGF9 affected MA-10 mouse Leydig tumor cell proliferation and found that FGF9 significantly induced cell proliferation by activating ERK1/2 and retinoblastoma (Rb) phosphorylations within 15 minutes. Subsequently, the expressions of E2F1 and the cell cycle regulators: cyclin D1, cyclin E1 and cyclin-dependent kinase 4 (CDK4) in G 1 phase and cyclin A1, CDK2 and CDK1 in S-G 2 /M phases were increased at 12 hours after FGF9 treatment; and cyclin B1 in G 2 /M phases were induced at 24 hours after FGF9 stimulation, whereas the phosphorylations of p53, p21 and p27 were not affected by FGF9. Moreover, FGF9- --
| INTRODUCTION
Fibroblast growth factors (FGFs), multifunctional proteins, have at least 22 members. 1 Fibroblast growth factor signaling has been reported to participate in many cell biological functions, such as proliferation, differentiation, survival and motility. [2] [3] [4] Four FGF receptors (FGFRs) have been identified in the human genome. 5 In addition to genomic difference, the mRNA of FGFRs could undergo alternative splicing to increase the protein diversity of FGFRs. 6 Thus, each FGF could interact with its specific FGFR to activate different signal pathways into cells. 7 Studies have shown that FGF/ FGFR signals participate in different cancer formations [8] [9] [10] : the abnormal or overexpression of FGFR1 could cause breast cancer and pancreatic adenocarcinoma, 11, 12 the isoform switch of FGFR2
and splice mutation is involved in prostate cancer and gastric cancer, 13 ,14 the mutation, overexpression and aberrant splicing of FGFR3 participates in thyroid cancer, cervical cancer and colorectal cancer, [15] [16] [17] and the higher expression of FGFR4 Arg388 allele in head and neck carcinoma is associated with poor survival. 18 It is well known that FGFRs couple to tyrosine kinase receptors, which will transduce outer stimulation through PI3K, MAPK and phospholipase Cγ (PLCγ) pathways. 5, 19 It was also shown that FGF could mediate FGFR activation to induce Akt phosphorylation and then to promote cell proliferation in nonsmall-cell lung cancer and nasopharyngeal carcinoma. 20, 21 The MAPK signaling pathway has three main signals: ERK1/2, JNK and p38. 22 In normal chondrocytes and pancreatic cancer cells, FGFRs could be activated by FGFs to induce cell proliferation through ERK1/2 phosphorylation. 23, 24 In hepatocellular carcinoma, FGFR-mediated ERK1/2 and JNK activations could increase the carcinogenesis and metastasis. 25 Activation of p38 is involved in gelsolin-induced osteosarcoma proliferation and high glucose-induced mesangial cell proliferation. 26, 27 Phospholipase C could receive the signal from FGFR and then cleave the phospholipid phosphatidylinositol 4,5-bisphosphate into diacylglycerol and inositol 1,4,5-triphosphate, 28 which would activate PLCγ1 to induce cell proliferation and migration in keratinocytes and vascular smooth muscle cells. 29, 30 Defects in cell division can lead to developmental abnormalities as well as tumor development and cancerous growth. The eukaryotic cell cycle is regulated by the activities of cyclin-dependent kinases (CDKs) and cyclins. 31 In different cell cycle phase, the concentrations of cyclins and CDKs fluctuate. In the complex of cyclin D/CDK4, 6
can be activated to phosphorylate the retinoblastoma protein (Rb) promoting cells into S phase. Cyclin E and A can be upregulated in S phase to increase CDK2 and CDK1 activities to promote cells into G 2 phase. Moreover, cyclin B will be upregulated at late G 2 phase and to interact with CDK1 to promote cells into mitosis. 32 When a cell is not suitable for division, the regulatory proteins, such as p53, p21 and p27, would be activated to interact with the cyclin/CDK complex interrupting the conformational change, which is required for complex activation to cause cell cycle arrest. 33, 34 Fibroblast growth factor 9 was first isolated from the culture supernatant of a human glioma cell line. 35 Studies have reported that FGF9 participates in palate formation, sex determination and lung development in the embryonic stage and has low expression levels under normal conditions in few adult organs. [36] [37] [38] However, abnormal expression of FGF9 might cause various cancer formations, [39] [40] [41] [42] and the mechanisms remain elusive.
Leydig cell tumors of the testis are a rare sex cord-stromal tumor, accounting 1%-3% of all testicular neoplasms and 4%-9% of testis tumors in prepubertal boys. [43] [44] [45] [46] Leydig cell tumors usually occur in prepubertal boys and men between 30 and 60 years of age. Leydig cell tumors are benign in children but can be malignant in 10% of adults. 46, 47 It has been reported that the expression of FGF9 is high in testicular cancer. 48 In the present study, FGF9-induced MA-10 mouse
Leydig tumor cell proliferation is reported for the first time, and the basic mechanisms how FGF9-induced MA-10 cells are revealed, which could be applied for the treatment of testicular and related cancers.
| MATERIALS AND METHODS

| Cell line and treatments
The MA-10 mouse Leydig tumor cell line was a gift from Dr. Mario Table S1 .
| Cell proliferation assay
MA-10 cells were seeded in 96-well plates at a density of 8000 cells per well. After serum-starved for 18 hours, the cells were treated with 0, 1, 10, 25 or 50 ng/mL FGF9 in medium containing 1% FBS.
Then MTT (0.5 mg/mL) was added at 24, 48, or 72 hours after the FGF9 treatment and incubated at 37°C for 4 hours. The medium was discarded, and DMSO was added to dissolve the crystals by shaking the plates for 20 minutes in the dark. The OD values were determined using an ELISA reader (Molecular Devices, San Jose, CA, USA) with a 570-nm filter. Table S2 . Immunoprecipitates were isolated using E2F1-conjugated protein G magnetic beads after 16 hours of incubation at 4°C, followed by immunoblot analysis.
| Western blot analysis
| Immunoprecipitation assay
| Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was carried out using the Magna ChIP G Kit (Table S1) (Table S1 ) for 24 hours in the dark. Samples were examined using the Olympus FluoView FV1000 confocal microscope (Olympus, Tokyo, Japan). Images were analyzed using the Olympus FluoView FV10-ASW software (Olympus).
| Knockdown of FGFR genes using lentiviral shRNAs
The pCMV-ΔR8.91, pMD.G, and all pLKO-based shRNA clones for FGFR1-4 and nonsilencing shRNA (scrambled sequence) were obtained from the National RNAi Core Facility at Academia Sinica (Taipei, Taiwan). All shRNA plasmids used in this study are described in Table S4 . Lentivirus preparation was carried out according to the supplier's protocols. MA-10 cells were infected with lentivirus in the presence of 8 μg/mL polybrene. For stable cell lines, cells were selected by 5.5 μg/mL puromycin 48 hours after infection and maintained in growth medium containing 5.5 μg/mL puromycin.
| Animals and treatments
NOD/SCID (NOD.CB17-Prkdc scid /NcrCrl) male mice (12 weeks old)
were purchased from National Cheng Kung University Animal Center 
| Statistical analysis
Statistical analysis was carried out using Prism 6 software (GraphPad, La Jolla, CA, USA). P < .05 was considered to be statistically significant in this study.
| RESULTS
| FGF9 increased cell proliferation rate in
MA-10 cells
In this study, MTT assay was used to confirm the effect of FGF9 on cell proliferation in MA-10 mouse Leydig tumor cells. Different doses of FGF9 (1-50 ng/mL) were used to treat MA-10 cells, and results
showed that 50 ng/mL FGF9 exposure for 24, 48, and 72 hours could significantly induce cell proliferation in MA-10 cells (Figure 1A ). In addition, the expression of Ki-67, a standard marker of proliferation that is commonly used to assess the growth fraction of a cell population, 49 significantly increased at 12 hours after FGF9 treatment ( Figure 1B ). These data highly suggested that FGF9 could induce MA-10 mouse Leydig tumor cell proliferation. 52 Here, for studying cell cycle signaling, 18-hours serum-starved MA-10 cells were treated without or with 50 ng/ml FGF9 for 0, 0.25, 0.5, 1, 3, or 6 hours, and the protein expressions related to PI3K, MAPK, and PLCγ signaling pathways were examined. Results showed that FGF9 had no effect on the F I G U R E 1 Fibroblast growth factor 9 (FGF9) induced MA-10 cell proliferation and MAPK pathway. MA-10 cells were starved for 18 hours, and then treated with 50 ng/mL FGF9 or PBS for 12, 24, 48, or 72 hours. A, MTT assay for the viability of treated MA-10 cells. B, Western blot analysis of Ki-67 expression in treated MA-10 cells. C-E, Western blot analysis for expression of (C) phosphor-mTOR and total mTOR, (D) phosphor-ERK1/2 and total ERK1/2, and (E) phosphor-phospholipase Cγ1 (PLCγ1) and total PLCγ1 in MA-10 cells treated with 50 ng/mL FGF9 or PBS for 0, 0.25, 0.5, 1, 3, or 6 hours. All values are represented as the mean ± SEM, n = 3. P values were calculated using one-way ANOVA with Tukey's multiple comparisons post-tests. *P < .05, **P < .01, ***P < .001 vs the control group phosphorylation of mTOR, a downstream molecule of Akt protein in MA-10 cells ( Figure 1C ). In the MAPK pathway, FGF9 (50 ng/mL) from 0.25 to 3 hours did significantly induce the phosphorylation of ERK1/2 ( Figure 1D ). However, FGF9 had no effect on the phosphorylation of PLCγ1 ( Figure 1E ) in MA-10 cells. Thus, FGF9 could activate ERK1/2 phosphorylation related to cell proliferation in MA-10 cells.
| FGF9 induced the expression of cell cyclerelated proteins in MA-10 cell proliferation
The cell cycle control system depends on cyclically activated
CDKs, and the activities of CDKs are controlled by different cyclins, which undergo a cycle of synthesis and degradation in each cell cycle. 53 Thus, changes in the expressions of cell cyclerelated proteins in MA-10 cells after treatment with 50 ng/mL FGF9 were examined.
In G 1 phase-related proteins, the expressions of cyclin D1, CDK4, and cyclin E1 were increased at 12 hours after 50 ng/mL FGF9 treatment (Figure 2A-C) . In S/G 2 /M phase, the upregulation of CDK2, cyclin A1, and CDK1 were found at 12 hours after 50 ng/mL FGF9 treatment ( Figure 2D-F) .
These results highly suggested that FGF9 could regulate the expression of cyclin and CDK to regulate cell cycle progression for MA-10 cell proliferation.
F I G U R E 2 Fibroblast growth factor 9 (FGF9) induced expression of cell cyclerelated proteins in MA-10 cell proliferation. Western blot analysis for the expression of (A) cyclin D1, (B) cyclin-dependent kinase 4 (CDK4), (C) cyclin E1, (D) CDK2, (E) cyclin A1, and (F) CDK1 in MA-10 cells treated with 50 ng/mL FGF9 or PBS for 12, 24, or 48 h. All values are represented as the mean ± SEM, n = 3. P values were calculated using Student's t test. *P < .05, **P < .01, ***P < .001 vs control group
| FGF9 promoted Rb phosphorylation to induce
MA-10 cell proliferation
The concentration of cyclins and the activation status of CDKs directly control cell cycle progression. When it is not suitable for cell division, the regulatory proteins, such as p53, p21, and p27, are turned on to interact with the cyclin/CDK complex to suppress cell cycle progression for proliferation. 54, 55 Results showed that 50 ng/ mL FGF9 treatment for 12, 24, and 48 hours did not have any effect on the expression of p53, p21, or p27 in MA-10 cells (Figure 3A-C) .
In addition to the p53 signal pathway, Rb was also examined.
Retinoblastoma is a tumor suppressor protein, which could prevent abnormal cell growth by inhibiting cell cycle progression at the G 1 /S checkpoint. 56 Retinoblastoma loses its E2F binding activity when it is phosphorylated, free E2F is then able to transactivate its cell cycle-related target genes, resulting in the cell cycle progression and cell proliferation. [57] [58] [59] [60] [61] Results showed that treatment with 50 ng/mL FGF9 for 12, 24, and 48 hours significantly increased the phosphorylation of Rb in MA-10 cells ( Figure 3D ).
These data indicate that FGF9 had no effect on the p53
pathway, but suppressed the Rb pathway to induce MA-10 cell proliferation. F I G U R E 3 Fibroblast growth factor 9 (FGF9) increased retinoblastoma (Rb) phosphorylation, but had no effects on p53, p21, or p27 in MA-10 cells. Western blot analysis for the expression of (A) phosphor-p53 and p53, (B) p21, (C) phosphor-p27 and p27, and (D) phosphorRb in MA-10 ells treated with 50 ng/mL FGF9 or PBS for 12, 24, or 48 h. The integrated optical density of phosphorproteins was normalized to that of their total protein and corrected by their control group at each time point. Quantitative values are represented as the mean ± SEM, n = 3. P values were calculated using Student's t test. *P < .05, **P < .01, ***P < .001 vs control group F I G U R E 4 Fibroblast growth factor 9 (FGF9) enhanced retinoblastoma (Rb)/E2F and cell cycle pathways by activating ERK1/2. After 18 hours of serum starvation, MA-10 cells were treated with 50 μmol/L PD98059 for 1 hour, and then treated with 50 ng/mL FGF9 and/or PD98059 for 0.25, 12, or 24 hours. Expression of (A) phosphor-ERK1/2 and total ERK1/2, (B) phosphor-Rb and E2F1, (C) cyclin D1, E1, A1, and B1, and (D) cyclin-dependent kinase 4 (CDK4), CDK2 and CDK1 at various time periods were analyzed by western blot. Quantitative values are represented as the mean ± SEM, n = 4. P values were calculated using one-way ANOVA with Tukey's multiple comparisons posttests. *P < .05, **P < .01, ***P < .001 vs control group (without FGF9 and PD98059 treatment) at each time point. #P < .05, ##P < .01, ###P < .001 vs FGF9 group (without PD98059 treatment) at each time point
| FGF9 stimulated dissociation of Rb-E2F1 complexes and enhanced transactivations of E2F target genes
The consequence of increased Rb phosphorylation is the dissociation of the Rb-E2F complexes, the transactivation of E2F target genes, cell cycle progression, and cell proliferation. [57] [58] [59] [60] [61] To test whether FGF9 could increase the release of Rb-bound E2F1 by enhancing phosphorylation of Rb at 15 minutes after treatment, IP assay was carried out. The results showed that the level of Rb-E2F1 complexes dramatically decreased at 1 hour, but did not differ significantly at 15 minutes, after FGF9 treatment ( Figure 5A ). These results suggest that after FGF9 stimulation, Rb was hyperphosphorylated and then subsequently lost its grip on E2F1.
A number of studies have reported that E2F1 directly transactivates its target genes involved in the G 1 /S transition and S phase, such as Cyclin D1, Cyclin E1, Cyclin A1, cdc25C, and cdc2 genes.
58,62-
65 Also, Figure 4C shows the protein levels of Cyclin D1, Cyclin E1, and Cyclin A1 were upregulated at 12 hours after FGF9 treatment, Cyclin A1 genes through the E2F1 binding site.
F I G U R E 5
Fibroblast growth factor 9 (FGF9) increased the release of retinoblastoma (Rb)-bound E2F1 and enhanced E2F1 transcriptional activity. MA-10 cells were starved for 18 hours then treated with 50 ng/mL FGF9 or PBS for 0.25 or 1 h. A, Immunoprecipitation (IP) with anti-E2F1-or rabbit IgG (negative control)-conjugated magnetic G beads was carried out in the cell lysates from treated MA-10 cells. Western blots were probed with anti-Rb, anti-phosphor-Rb (S807/S811), and anti-β-actin. B, Schematic representation of Cyclin D1, Cyclin E1, and Cyclin A1 promoters highlighting the E2F1 binding motif positions in relation to the transcription start site. [63] [64] [65] Horizontal arrows indicate the location of specific primers used for ChIP-quantitative PCR (qPCR) assays. Note that the figure is not drawn to scale. C, ChIP was carried out using anti-E2F1 or rabbit IgG Abs followed by qPCR analyses. ChIP-enriched DNA was amplified with the primers for E2F1 binding regions on the promoter of Cyclin D1, Cyclin E1, and Cyclin A1 genes. The ChIP-qPCR data were represented as fold changes compared with the PBS control group after normalized to the IgG control. Values are presented as the mean ± SEM, n = 4. P values were analyzed using Student's t test. *P < .05, **P < .01, ***P ≤ .001 showed that the tumor volumes of the FGF9-treated group were significantly higher than that of vehicle and control (no treatment) groups ( Figure 9A ) and the tumor weights significantly increased with FGF9 treatment (vehicle group, 3.27 ± 0.17 g; control group, 3.08 ± 0.27 g; and FGF9-treated group, 4.62 ± 0.54 g) ( Figure 9B ).
There was no significant difference in body weight between control, and PBS-and FGF9-treated mice, indicating that FGF9 treatment had an acceptable safety profile (P > .05; Figure 9A inset).
To further investigate the tumor growth-promoting effects of FGF9 in vivo, immunohistochemistry examinations of Ki-67, cleaved caspase-3, and FGF9, with serial sections, were carried out. Results showed that the tumor tissue expressions of Ki-67 increased and cleaved caspase-3 decreased when the expression of FGF9 increased ( Figure 9C ). These results suggest that, in vivo, FGF9 promoted tumor growth by increasing cell proliferation and decreasing cell death, apoptosis.
Furthermore, the immunohistochemical expression of phosphor-ERK1/2, phosphor-Rb, and E2F1 in MA-10 tumors was significantly increased in the FGF9-treated group compare to control and PBS groups ( Figure 9D ). These in vivo observations further support that FGF9 promoted cell proliferation by activating the ERK1/2 and RB/ E2F pathways in vitro (Figure 4 ). In conclusion, FGF9 significantly promoted tumor growth in both an in vitro cellular system and an in vivo animal model related to tumorigenesis.
| DISCUSSION
In this study, we showed that FGF9, via FGFR2, significantly pro- . Quantification values are represented as the mean ± SEM; n = 4. P values were calculated using one-way ANOVA with Tukey's multiple comparisons posttests. *P < .05, **P < .01, ***P < .001 vs control group. Thus, our observation that FGF9 exerted cell proliferation in MA-10 cells is not unprecedented. However, no report has described the role of FGF9 in inducing cell proliferation in testicular tumor.
To investigate the mechanism of action, the activation profile of the PI3K, MAPK, and PLCγ signaling pathways in FGF9-treated MA-10 cells was studied. Our data showed FGF9 had no effect Thus, our observations are consistent with those studies.
Regarding cell cycle inhibitory proteins, p53 is a tumor suppressor that can induce the expression of p21 and p27 proteins to further induce cell cycle arrest. 79 Moreover, retinoblastoma, a tumor suppressor protein, could prevent abnormal cell growth by suppressing E2F activity and inhibiting cell cycle progression at the G 1 /S F I G U R E 1 0 Summary scheme illustrating how fibroblast growth factor 9 (FGF9) induces MA-10 cell proliferation. FGF9 associates with FGF receptor 2 (FGFR2) to stimulate retinoblastoma (Rb) phosphorylation through ERK1/2 activation. FGF9-induced Rb phosphorylation leads to the release of Rbbound E2F resulting in the nuclear translocation of E2F1 and transactivation of E2F target genes. FGF9 significantly increases the expression of E2F and cell cycle related proteins, cyclins and cyclindependent kinases (CDKs), to increase cell cycle progression, which finally promotes MA-10 cell proliferation.
checkpoint. Retinoblastoma loses its grip on E2F when it is phosphorylated, free E2F is then able to translocate to the nuclues and transactivate its cell cycle-related target genes to promote cell cycle and cell proliferation. 56, 80 In the present study, the expression of p53, p21, and p27 was not affected by FGF9, indicating the p53 pathway did not have any role in suppressing MA-10 cell proliferation. Moreover, FGF9 increased the expression of phosphor-Rb, suggesting MA-10 cell proliferation was not suppressed by the Rb and E2F pathway. Neither the p53 nor Rb inhibitory pathways regulating cell cycle progression were functioning, which would certainly cause MA-10 cell proliferation. In fact, studies have illustrated that cell proliferation in various tumors is due to the inactivation of the p53 pathway and the suppression of Rb pathway. 81 Thus, our observations are not exceptional.
In this study, the xenograft model results showed that FGF9 significantly induced in vivo MA-10 tumor growth, a result of increased cell proliferation and decreased cell death. There was no toxicity or side-effects associated with FGF9 treatment as there was no difference in body weight between control and FGF9-treated groups. To our knowledge, this is the first study to assess the proliferative efficacy of FGF9 on testicular cancer in vivo.
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